At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 5, 2026 at 09:28 ET
Evaxion reported strong 2025 financial and clinical progress, highlighted by a $7.5M upfront from MSD for its AI-discovered vaccine EVX-B3, improved cash position of $23.2M extending runway into 2027, and compelling phase 2 data for its cancer vaccine EVX-01 showing 75% objective response rate in advanced melanoma. The company also expanded its pipeline and secured enhanced funding capacity via an amended ATM program allowing up to $45.5M in future share issuances.
- Received $7.5M from MSD for the option exercise on infectious disease candidate EVX-B3, with potential for up to $592M in milestone payments
- Cash and cash equivalents increased to $23.2M (from $6.0M in 2024), funding operations into H2 2027
- EVX-01 showed 75% objective response rate and 92% durable clinical benefit at two years in phase 2 melanoma trial
- Net loss narrowed to $7.7M in 2025 from $10.6M in 2024, driven by higher revenue and lower R&D and G&A expenses
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access